Supernus Pharmaceuticals (SUPN) PT Raised to $47 at Piper Sandler
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $48.27 +2.38%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Piper Sandler analyst David Amsellem raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $47.00 (from $40.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- KP Tissue Inc. (KPT:CN) (KPTSF) PT Raised to Cdn$13.50 at Desjardins
- Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
